

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. 利君國際醫藥(控股)有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

BUSINESS UPDATE

This announcement is made by SSY Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Insider Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to announce that on 8 June 2015, Hebei Hanlin Biotechnology Co., Ltd., a joint venture company of the Company, has obtained 6 production approvals on serum free media for stem cell (including lymphocyte serum free medium, human tissue serum free medium, epidermal serum free medium, high density cell culture medium, epithelial serum free medium and fibroblast serum free medium). This type of products is mainly useful in stem cell based-researches, medicine research and development as well as future therapeutic applications and has a board market prospect.

The board also announces that Shijiazhuang No.4 Pharmaceutical Co., Ltd, a wholly-owned subsidiary of the Group, has obtained the production approvals of polypropylene ampule package for glucose injection (20ml:10g) and sterile water for injection (2ml). In terms of clinical application, this type of products is complementary to the Group’s intravenous infusion solution products.

With the aforesaid production approvals obtained, these products can be sold in the market when the production facilities pass the GMP certification.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 15 June 2015

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.